In the shadow of a global diabetes epidemic and an aging population, chronic wounds—diabetic foot ulcers, venous leg ulcers, pressure injuries—represent a silent, growing, and devastating healthcare crisis. These are not simple cuts; they are complex biological failures where the healing process stalls, often indefinitely.
The financial burden is staggering, with estimates for annual US wound care costs exceeding $28 billion. Most chillingly, chronic wounds are the leading cause of non-traumatic lower limb amputations, with a diabetic patient losing a limb every 22 seconds somewhere in the world.
Rapid Nexus Nanotech Wound Solutions, a California-based medical-device developer, has approached the problem a different way. The company’s solutions focus on a different culprit: the degraded, ischemic, and denervated tissue surrounding the wound, known as the periwound. This “living edge” is often so compromised, in cases of chronic wounds, that it cannot orchestrate the complex cellular symphony required for closure. The result is a frustrating cycle of intervention and deterioration.
The company recently secured a US Food and Drug Administration (FDA) 510(k) clearance for Hemastyl Gel, the first technology specifically engineered to treat this critical periwound tissue.
In an interview with the Drug and Device World, Rapid Nexus’s CEO and founder, Dr. Margaret Kalmeta, detailed this revolutionary shift, explaining the science of the “dual-system,” the roadmap for patient access, and her ultimate vision: to make preventable amputations a relic of the past.